Cytokines in the microenvironment of Waldenström's macroglobulinemia

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 43-45

  Elsawa, Sherine ^a   Ansell, Stephen ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Angiogenin; Angiopoeitin; B lymphocyte stimulator; Vascular endothelial growth factor; Waldenstr m

Indexed keywords

ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; B CELL ACTIVATING FACTOR; CYTOKINE; IMMUNOGLOBULIN; INTERLEUKIN 6; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN;

ARTICLE; B LYMPHOCYTE; BONE MARROW; CANCER CELL; CANCER GROWTH; CYTOKINE PRODUCTION; HUMAN; IMMUNOGLOBULIN PRODUCTION; MICROENVIRONMENT; PROTEIN EXPRESSION; WALDENSTROEM MACROGLOBULINEMIA; ANIMAL; BIOSYNTHESIS; IMMUNOLOGY; REVIEW;

ANIMALS; B-LYMPHOCYTES; CYTOKINES; HUMANS; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649553516     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.010     Document Type: Article

References (25)

1. Kyle RA, Vincent Rajkumar S. Monoclonal gammopathies of undetermined significance. Best Pract Res Clin Haematol 2005; 18:689-707.
2. Tournilhac O, Santos DD, Xu L, et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 2006; 17:1275-82.
3. Villanueva J, Herlyn M. Melanoma and the tumor microenvironment. Curr Oncol Rep 2008; 10:439-46.
4. Farrow B, Albo D, Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res 2008; 149:319-28.
5. Nagasawa T. Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol 2006; 6:107-16.
6. Mackay F, Schneider P, Rennert P, et al. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003; 21:231-64.
7. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189:1747-56.
8. Kishimoto T. The biology of interleukin-6. Blood 1989; 74:1-10.
9. Akira S, Kishimoto T. The evidence for interleukin-6 as an autocrine growth factor in malignancy. Semin Cancer Biol 1992; 3:17-26.
10. Terpos E, Anagnostopoulos A, Kastritis E, et al. Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstrom macroglobulinaemia. Br J Haematol 2006; 133:301-4.
11. Anagnostopoulos A, Eleftherakis-Papaiakovou V, Kastritis E, et al. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br J Haematol 2007; 137:560-8.
12. Ngo HT, Leleu X, Lee J, et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 2008; 112:150-8.
13. Novak AJ, Bram RJ, Kay NE, et al. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002; 100:2973-9.
14. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103:3148-57.
15. Elsawa SF, Novak AJ, Grote DM, et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom's macrolobulinemia. Blood 2006; 107:2882-8.
16. Pedersen LM, Jurgensen GW, Johnsen HE. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma. Br J Haematol 2005; 128:813-9.
17. Aldinucci D, Lorenzon D, Olivo K, et al. Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Sternberg cells. Leuk Lymphoma 2004; 45:1731-9.
18. Arendt BK, Velazquez-Dones A, Tschumper RC, et al. Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells. Leukemia 2002; 16:2142-7.
19. French JD, Walters DK, Jelinek DF. Transactivation of gp130 in myeloma cells. J Immunol 2003; 170:3717-23.
20. Hirano T. Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias. Int J Cell Cloning 1991; 9:166-84.
21. Hatzimichael EC, Christou L, Bai M, et al. Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstrom's macroglobulinemia. Eur J Haematol 2001; 66:1-6.
22. Chng WJ, Schop R, Price-Troska T, et al. Gene expression profiling of Waldenstrom's macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006; 108:2755-63.
23. Hatjiharissi E, Ngo H, Leontovich AA, et al. Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res 2007; 67:3777-84.
24. Fischer FR, Luo Y, Luo M, et al. RANTES-induced chemokine cascade in dendritic cells. J Immunol 2001; 167:1637-43.
25. Nanki T, Nagasaka K, Hayashida K, et al. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol 2001; 167:5381-5.